BioSpace News Archive

The company will use the latest funding to further advance its telemedicine platform and accelerate its sales and marketing efforts.

First-ever human use of eRapa in clinical trial at UT Health San Antonio MD Anderson Cancer Center will test safety, effective dose and tolerability in early-stage prostate cancer patients, and explore how the drug could boost the immune system for a multitude of age-related diseases

enter For Discovery, the largest provider of eating disorders treatment in Southern California and a leader nationwide with more than 60 residential and outpatient facilities, has opened its latest center in Glendale, Calif., it was announced today.

Signature Performance, Inc. (SPI) announces that it was awarded a GSA/FAS schedule contract for Information Technology (IT) Schedule 70 for its technology equipment, software and services under IT Professional Services SIN 132-51 and Health IT Services SIN132-56.

CRCC and Digitec Interactive won a coveted Brandon Hall Group silver award for excellence in the Best Use of Section 508 Requirements for Training Programs category. CRCC e-UNIVERSITY provides a flexible learning portal for rehabilitation counselors to maintain their CRC certification.

The Tampa Bay Rays have completed construction of a Recovery Room Powered by NormaTec. Located under the dome at Tropicana Field

Amy Price, MA, LCPC, Clinical Director of Terra Counseling & Consulting, Inc (Terra), was appointed to the Board of Directors at Baltimore-based human trafficking abolitionist non-profit, Araminta Freedom Initiative, Inc (Araminta). The vision of Araminta is to see every child free from human trafficking.

Yesterday, global standards developer ASTM International announced its first round of funding to support research that will help catalyze the development of needed standards in additive manufacturing, also known as 3D printing

The live national simulcast will feature expert clinical and oncology pharmacists from Indiana University Health

Integral Molecular, , the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that they have entered into a collaboration on multiple undisclosed targets.